| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K27188169:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0042 | 0.9 |
| mRNA | Sunitinib | FIMM | pan-cancer | AAC | -0.014 | 0.9 |
| mRNA | BMS-270394 | CTRPv2 | pan-cancer | AAC | 0.003 | 0.9 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | -0.0027 | 0.9 |
| mRNA | GSK-1904529A | GDSC1000 | pan-cancer | AAC | -0.0025 | 0.9 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | 0.0024 | 0.9 |
| mRNA | PF-3758309 | CTRPv2 | pan-cancer | AAC | 0.0031 | 1 |
| mRNA | myriocin | CTRPv2 | pan-cancer | AAC | -0.0049 | 1 |
| mRNA | Methotrexate | FIMM | pan-cancer | AAC | 0.0077 | 1 |
| mRNA | XMD8-92 | GDSC1000 | pan-cancer | AAC | 0.0023 | 1 |